News Releases

News Releases

Date Title
Aug 14, 2017
Summary ToggleOpiant CEO Roger Crystal Appears on Fox News Channel to Discuss the Opioid Crisis Being Declared a National Emergency
Aug 10, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization
Aug 04, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent
Jul 27, 2017
Summary ToggleOpiant CEO Roger Crystal Appears on Fox & Friends
Jul 26, 2017
Summary ToggleOpiant CEO Roger Crystal Appears on Fox Business Network
Jul 19, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development for the Treatment of Alcohol Use Disorder
Jun 28, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Licenses Aegis Therapeutics’ Intravail® Drug Delivery Technology
Jun 27, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent
Jun 15, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update
Mar 27, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Announces Results of Positron Emission Tomography (PET) Study of Naloxone Nasal Spray
Mar 20, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
Mar 16, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update
Mar 09, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings for Two New NARCAN® Nasal Spray Patents
Feb 28, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Receives FDA Feedback Supporting Clinical Development of OPNT002 for the Treatment of Alcohol Use Disorder
Feb 06, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer
Jan 31, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Announces Establishment of Audit, Compensation and Nominating and Corporate Governance Committees
Jan 26, 2017
Summary ToggleOpiant Pharmaceuticals, Inc. Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI) Nasal Spray
Jan 11, 2017
Summary ToggleOpiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals
Jan 09, 2017
Summary ToggleOpiant Pharmaceuticals Featured in Recent Media Highlighting NARCAN® Nasal Spray and Heroin Vaccine Development